These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29685422)

  • 1. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
    Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of high serum CXCL13 level in Waldenström macroglobulinemia.
    Wu YY; Cai H; Zhao AL; Zhang L; Zhou DB; Cao XX; Li J
    Leuk Res; 2019 Jun; 81():50-55. PubMed ID: 31015152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients.
    Terpos E; Tasidou A; Eleftherakis-Papaiakovou E; Christoulas D; Gavriatopoulou M; Gkotzamanidou M; Roussou M; Kastritis E; Papadaki T; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):115-7. PubMed ID: 21454208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.
    García-Sanz R; Dogliotti I; Zaccaria GM; Ocio EM; Rubio A; Murillo I; Escalante F; Aguilera C; García-Mateo A; García de Coca A; Hernández R; Dávila J; Puig N; García-Álvarez M; Chillón MDC; Alcoceba M; Medina A; González de la Calle V; Sarasquete ME; González M; Gutiérrez NC; Jiménez C
    Br J Haematol; 2021 Mar; 192(5):843-852. PubMed ID: 32780894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
    Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
    Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia.
    Kristinsson SY; Björkholm M; Landgren O
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):187-90. PubMed ID: 23490991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.
    Varettoni M; Zibellini S; Capello D; Arcaini L; Rossi D; Pascutto C; Rattotti S; Mangiacavalli S; Pochintesta L; Gotti M; Gaidano G; Cazzola M
    Leuk Lymphoma; 2013 Nov; 54(11):2485-9. PubMed ID: 23442064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
    Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
    Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
    Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
    Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Papasotiriou I; Fotiou D; Migkou M; Roussou M; Kanellias N; Ziogas D; Dialoupi I; Eleutherakis Papaiakovou E; Kastritis E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):23-28. PubMed ID: 30224328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and Prognosis of Patients with Immunoglobulin M Monoclonal Gammopathy.
    Tanaka H; Sakuma Y; Ikeda H; Shimizu R; Sugita Y; Iwai R
    J Clin Exp Hematop; 2017; 57(2):47-53. PubMed ID: 29021514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism.
    Jalali S; Shi J; Ahsan N; Wellik L; Serres M; Buko A; Paludo J; Kim H; Tang X; Yang ZZ; Novak A; Kyle R; Ansell S
    Redox Biol; 2021 May; 41():101927. PubMed ID: 33690107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis in Waldenström's macroglobulinemia.
    Terpos E; Tasidou A; Kastritis E; Eleftherakis-Papaiakovou E; Gavriatopoulou M; Migkou M; Dimopoulos MA
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):46-9. PubMed ID: 19362971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cellular origin and malignant transformation of Waldenström macroglobulinemia.
    Paiva B; Corchete LA; Vidriales MB; García-Sanz R; Perez JJ; Aires-Mejia I; Sanchez ML; Barcena P; Alignani D; Jimenez C; Sarasquete ME; Mateos MV; Ocio EM; Puig N; Escalante F; Hernández J; Cuello R; García de Coca A; Sierra M; Montes MC; González-López TJ; Galende J; Bárez A; Alonso J; Pardal E; Orfao A; Gutierrez NC; San Miguel JF
    Blood; 2015 Apr; 125(15):2370-80. PubMed ID: 25655603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Gomez Mediavilla A; Urquieta Lam M; Insunza A; Tonda R; Beltran S; Gut M; Gonzalez A; Montes-Moreno S
    J Clin Pathol; 2020 Sep; 73(9):571-577. PubMed ID: 31980558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.
    Ahn A; Park CJ; Cho YU; Jang S; Seo EJ; Lee JH; Yoon DH; Suh C
    Ann Lab Med; 2020 May; 40(3):193-200. PubMed ID: 31858758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.
    Kyle RA; Therneau TM; Dispenzieri A; Kumar S; Benson JT; Larson DR; Melton LJ; Rajkumar SV
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):184-6. PubMed ID: 23490989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.
    Andrade-Campos M; Murillo-Flórez I; García-Sanz R; Giraldo P
    Clin Chem Lab Med; 2017 Aug; 55(10):1598-1604. PubMed ID: 28284031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting transformation of asymptomatic IgM monoclonal gammopathy.
    Greco A; Tedeschi A; Varettoni M; Nichelatti M; Paris L; Ricci F; Vismara E; Morra E
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):77-9. PubMed ID: 21454196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenström macroglobulinemia.
    Chen J; Jia MN; Cai H; Li ZP; Li J; Zhou DB; Cao XX
    Ann Hematol; 2024 Sep; 103(9):3667-3675. PubMed ID: 38448788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.